Clinical Trial Update: A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]

View source ↗

Summary

Epizyme's Phase 1 study of EZM0414 (IPN60210) in relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma was terminated, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• EZM0414 (IPN60210) (IPN60210)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2025-05-11